CONSUN PHARMAC.GR.HD -10 Total Liabilities
CONSUN PHARMAC.GR.HD -10 total liabilities. Based on the latest financial reports, CONSUN PHARMAC.GR.HD -10 (C1P) has total liabilities worth €1.57 Billion EUR (≈ $1.84 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check C1P asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CONSUN PHARMAC.GR.HD -10 (2021–2025)
Total liabilities of CONSUN PHARMAC.GR.HD -10 from 2021 to 2025. This chart illustrates how CONSUN PHARMAC.GR.HD -10's total liabilities have evolved over time, based on quarterly financial data.
CONSUN PHARMAC.GR.HD -10 Competitors by Total Liabilities
The table below lists competitors of CONSUN PHARMAC.GR.HD -10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rianlon Corp
SHE:300596
|
China | CN¥5.58 Billion |
|
Hyprop
JSE:HYP
|
South Africa | ZAC15.71 Billion |
|
Luoyang Xinqianglian Slewing Bearin
SHE:300850
|
China | CN¥4.40 Billion |
|
BlackRock ESG Capital Allocation Trust
NYSE:ECAT
|
USA | $182.33 Million |
|
Beijing Gehua CATV Network Co Ltd
SHG:600037
|
China | CN¥2.77 Billion |
|
Orora Ltd
AU:ORA
|
Australia | AU$1.95 Billion |
|
Befar Group Co Ltd
SHG:601678
|
China | CN¥12.07 Billion |
|
Nolato AB (publ)
ST:NOLA-B
|
Sweden | Skr4.36 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down CONSUN PHARMAC.GR.HD -10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CONSUN PHARMAC.GR.HD -10 (C1P) total assets.
Liquidity & Leverage Metrics
CONSUN PHARMAC.GR.HD -10 Total Liabilities Ratios Explained
CONSUN PHARMAC.GR.HD -10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CONSUN PHARMAC.GR.HD -10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CONSUN PHARMAC.GR.HD -10 (2021–2025)
The table below shows the annual total liabilities of CONSUN PHARMAC.GR.HD -10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.57 Billion ≈ $1.84 Billion |
+7.68% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
-8.13% |
| 2023-12-31 | €1.59 Billion ≈ $1.86 Billion |
+9.35% |
| 2022-12-31 | €1.45 Billion ≈ $1.70 Billion |
+0.10% |
| 2021-12-31 | €1.45 Billion ≈ $1.70 Billion |
-- |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more